Cathay Innovation
Assembly Line
AQEMIA Hits $100 Million Funding Milestone, Paving Way to Clinical Trials and Global Expansion Starting with London, UK
AQEMIA, a pioneering techbio that teaches atomic scale physics to a generative AI to invent innovative medicines, announces two major milestones: $100 million in cumulative funding and the beginning of a global expansion starting with London (United Kingdom).
The new $38 million funding round, led by new investor Cathay Innovation, brings total funds raised since inception to over $100 million. This round, coming less than a year after the previous one, follows the successful validation of AQEMIA’s drug discovery platform through outstanding results in internal preclinical programs and pharmaceutical partnerships, particularly in oncology. The funding will support AQEMIA’s development goals, including preparations for clinical trials.
AQEMIA will also use the proceeds to continue to advance its technology platform—teaching quantum-inspired, atomic-scale physics to generative AI—to transform drug discovery, designing innovative and safe small-molecule drugs with high efficiency. By teaching theoretical physics to the generative AI, AQEMIA does not need experimental data to train on, unlocking truly innovative molecular designs, further away from existing molecules—a key challenge for genAI. The drug discovery platform is now proven to work, as demonstrated by AQEMIA’s recent preclinical successes: (i) in their most advanced oncology programs with in vivo results, which continue to progress toward clinical trials, and (ii) through AQEMIA’s $140 million collaboration with Sanofi, announced in December 2023, which already underscored the platform’s potential and strong industry recognition.
Entalpic raises €8.5 Million to pioneer AI solutions for decarbonizing industrial chemistry
Entalpic, an innovative startup at the forefront of generative AI technology for materials discovery targeted to the chemical industry, announced today that it has successfully secured €8.5 million in seed funding. This investment is led by Breega, Cathay Innovation & Felicis, alongside contributions and insights from industry and academic advisors Jörg Weiser (ex-Managing Director at Schrödinger), Gilles Wainrib (co-founder at Owkin), Thomas Wolf (CSO and co-founder at Hugging Face), Arnaud Robert (ex C-level at Sanofi), Michal Valko (Principal LLama Engineer at Meta, ex-Deepmind) and Yoshua Bengio (Turing award, founder and scientific director at Mila). Entalpic emerges from a collaboration between researchers at Mila, the world’s premier research lab specializing in machine learning for climate action, and a leading executive from Owkin, a unicorn company renowned for its use of AI in drug discovery. Leveraging this expertise, Entalpic is set to redefine material and molecule discovery for a more sustainable future.
Entalpic’s state-of-the-art AI platform is designed to generate and evaluate new materials and molecules that could replace outdated industrial chemical processes. This platform swiftly formulates and tests chemical hypotheses through a series of automated experiments, enriching the knowledge base with actionable data. By integrating diverse data sources—from numerical quantum simulations and physical lab experiments to academic literature and patents—Entalpic leverages the latest in AI technology, including Large Language Models (LLMs), Active Learning and Graph Neural Networks.